## <sup>1</sup> Genomic and clinical characteristics of campylobacteriosis in Australia

- 2 Danielle M Cribb<sup>1\*</sup>, Cameron RM Moffatt<sup>2</sup>, Rhiannon L Wallace<sup>3</sup>, Angus T McLure<sup>1</sup>, Dieter Bulach<sup>4,5</sup>,
- 3 Amy V Jennison<sup>2</sup>, Nigel French<sup>6</sup>, Mary Valcanis<sup>5</sup>, Kathryn Glass<sup>1</sup>, Martyn D Kirk<sup>1</sup>.
- 4 1. National Centre for Epidemiology and Population Health, the Australian National University,
- 5 Canberra, Australia
- 6 2. Queensland Health Forensic and Scientific Services, Coopers Plains, Brisbane, Australia
- 7 3. Agriculture and Agri-Food Canada, Agassiz Research and Development Centre, Agassiz,
- 8 British Columbia, Canada
- 9 4. Melbourne Bioinformatics, The University of Melbourne, Melbourne, Australia
- 10 5. Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for
- 11 Infection and Immunity, The University of Melbourne, Melbourne, Australia
- 12 6. Tāwharau Ora|School of Veterinary Science, Massey University, Palmerston North, New
- 13 Zealand
- 14
- 15 \* corresponding author
- 16 [Danielle.Cribb@anu.edu.au](mailto:Danielle.Cribb@anu.edu.au) (DC)

17

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## <sup>18</sup> **Abstract**

19 *Campylobacter* spp. are a common cause of bacterial gastroenteritis in Australia, primarily acquired 20 from contaminated meat. We investigated the relationship between genomic virulence characteristics 21 and the severity of campylobacteriosis, hospitalisation, and other host factors.

22 We recruited 571 campylobacteriosis cases from three Australian states and territories (2018–2019). 23 We collected demographic, health status, risk factors, and self-reported disease data. We whole 24 genome sequenced 422 *C. jejuni* and 84 *C. coli* case isolates along with 616 retail meat isolates. We 25 classified case illness severity using a modified Vesikari scoring system, performed phylogenomic 26 analysis, and explored risk factors for hospitalisation and illness severity.

27 On average, cases experienced a 7.5-day diarrhoeal illness with additional symptoms including 28 stomach cramps (87.1%), fever (75.6%), and nausea (72.0%). Cases aged ≥75 years had milder 29 symptoms, lower Vesikari scores, and higher odds of hospitalisation compared to younger cases. 30 Chronic gastrointestinal illnesses also increased odds of hospitalisation. We observed significant 31 diversity among isolates, with 65 *C. jejuni* and 21 *C. coli* sequence types. Antimicrobial resistance genes 32 were detected in 20.4% of isolates, but multidrug resistance was rare (0.04%). Key virulence genes 33 such as *cdtABC* (*C. jejuni*) and *cadF* were prevalent (>90% presence) but did not correlate with disease 34 severity or hospitalisation. However, certain genes appeared to distinguish human *C. jejuni* cases from 35 food source isolates.

36 Campylobacteriosis generally presents similarly across cases, though some are more severe. 37 Genotypic virulence factors identified in the literature to-date do not predict disease severity but may 38 differentiate human *C. jejuni* cases from food source isolates. Host factors like age and comorbidities 39 have a greater influence on health outcomes than virulence factors.

40 Keywords: antimicrobial resistance, Campylobacter, clinical outcomes, severity, virulence, whole 41 genome sequencing.

# <sup>42</sup> **Author summary**

43 This study focused on *Campylobacter,* a common cause of gastroenteritis in Australia. We explored 44 the relationship between *Campylobacter's* genomic characteristics and disease severity, 45 hospitalisation, and host-related factors.

46 In 2018 – 2019, we collected data from 571 campylobacteriosis cases from Eastern Australia, focusing 47 on demographics, health status, risk factors, and self-reported symptoms. We sequenced 422 *C. jejuni*  48 and 84 *C. coli* case isolates and 616 retail meat isolates. We used a modified Vesikari scoring system 49 to assess illness severity, performed phylogenomic analysis, and explored hospitalisation and severity 50 risk factors.

51 Cases experienced an average 7.5-day period of diarrhoea with additional symptoms including 52 stomach cramps, fever, and nausea. Older individuals (75+ years) had milder symptoms but a higher 53 chance of hospitalisation. Those with chromic gastrointestinal conditions faced increased 54 hospitalisation odds. Case isolates showed considerable diversity. Antimicrobial resistance genes were 55 detected in some isolates, but multidrug resistance was rare. Virulence genes did not predict severity 56 or hospitalisation, but some genes did differentiate between case and food source *C. jejuni* isolates. 57 Host-related factors including age and comorbidities are more important in determining health 58 outcomes.

# <sup>60</sup> **Introduction**

61 *Campylobacter* spp. are the most commonly reported cause of bacterial gastroenteritis globally [1], 62 with Australia having among the highest rates in industrialised countries [2-4]. Most *Campylobacter*  63 infections are acquired from consumption of contaminated meat, primarily poultry [1, 5, 6]. The 64 clinical features of campylobacteriosis range from mild acute illness with diarrhoea, abdominal 65 cramps, and fever to severe enterocolitis with prolonged abdominal pain and bloody diarrhoea [7, 8]. 66 While disease is mostly self-limiting, some cases require antimicrobial therapy and hospitalisation [7, 67 9]. Some symptoms and host factors (e.g., age and chronic illness) are more likely to predict healthcare 68 use for acute gastrointestinal illness [10, 11]. Previous studies have found vomiting, bloody diarrhoea, 69 infective dose, fever, and loss of appetite associated with longer illness duration and risk of 70 hospitalisation [12, 13].

71 Pathogen virulence and host susceptibility factors explored in microbiological studies may have 72 implications for disease presentation and outcomes for *Campylobacter* spp. However, specific 73 virulence mechanisms associated with severe illness have not been clearly defined due to the genetic 74 diversity and uniqueness of the pathogen [14-16]. The main mechanisms associated with pathogenesis 75 in enteric bacteria are motility, adhesion, colonisation, toxin production, invasion, and immune 76 modulation [8, 16-20].

77 Identifying specific genes or gene combinations responsible for particular virulence phenotypes 78 enables understanding of the mechanisms of *Campylobacter* infection. While microbiological studies 79 have identified genes associated with putative virulence factors, there is a lack of epidemiological 80 studies confirming the role these genes play in disease manifestation. In this study we characterise 81 notified Australian campylobacteriosis cases by severity and compare with the genomic characteristics 82 of *Campylobacter* spp. isolated from food and humans.

## <sup>83</sup> **Methods**

#### 84 **Case selection and recruitment**

85 We recruited 571 notified campylobacteriosis cases from the Australian Capital Territory (ACT), Hunter 86 New England health district of New South Wales (NSW), and Queensland (Qld) between February 2018 87 and October 2019, as part of a previously described large Australian study [6, 21]. Suspected 88 campylobacteriosis cases provided stool samples to local pathology laboratories to identify and isolate 89 the pathogen. Samples that were positive for *Campylobacter* spp. were reported to the state or 90 territory public health department. Isolates were referred to reference laboratories and processed for 91 whole genome sequencing (WGS). Cases, or their legal guardian if aged less than 18 years, provided 92 consent for study enrolment. Interviews were generally conducted within two weeks of laboratory 93 notification, by either ACT public health unit staff (ACT cases) or by a computer-assisted telephone 94 interview team (NSW and Qld cases). Interviewers collected information on case characteristics 95 (demographics, medication use, health conditions), a list of self-reported symptoms, and disease 96 characteristics. Cases were asked to confirm their diarrhoeal status during illness (>3 loose bowel 97 movements in any 24-hour period), the date of illness onset, that no household member had 98 diarrhoea or tested positive for *Campylobacter* in the four weeks prior to illness onset, and that they 99 had not travelled outside of Australia in the two weeks prior to illness onset [21].

### 100 **Modified Vesikari Scoring System**

101 We modified the Vesikari scoring system (VSS) [22] to characterise illness severity (Table 1): retained 102 duration of diarrhoea in days and maximum number of diarrhoeal stools in a 24-hour period; replaced 103 the 'treatment type' variable (i.e., rehydration or hospitalisation) with 'healthcare use' (primary care, 104 1–2 days in hospital, or ≥3 days in hospital), and; substituted the presence of symptoms for clinical 105 characteristics as these data were not collected from our self-reported cases. We defined 106 hospitalisation as being admitted overnight due to campylobacteriosis. These modifications are 107 consistent with studies that categorised bacterial gastroenteritis in paediatric cases [23, 24]. We

- 108 allocated equal weighting to variables associated with the course of disease as well as each reported
- 109 symptom apart from blood in stool, which was given two points (Table 1) [25]. We classified cut-offs
- 110 for mild, moderate, and severe disease as ≤8 points, 9–12 points, and ≥13 points respectively, in line
- 111 with previous scoring systems [22-24].





#### 113 **Food sample collection**

- 114 Raw chicken meat and offal (organ meat) and beef, lamb, and pork offal were collected from retail
- 115 outlets in NSW, Qld, and Victoria (chicken only) from 2017–2019, and from the ACT in 2018, as
- 116 previously described [26, 27]. Offal samples included giblets, neck, liver, kidney, heart, and tongue. As
- 117 *Campylobacter* spp. prevalence is generally low on beef, lamb, and pork meat, offal was sampled to
- 118 obtain a suitable number of isolates for WGS.

### 119 **Whole genome sequencing and genomic analysis**

- 120 For each *Campylobacter* isolate, genomic DNA was extracted and WGS was performed using an
- 121 Illumina NextSeq500 (Illumina, San Diego, California, USA) as described previously [27]. In total, we
- 122 sequenced 508 isolates from human stool samples and 616 isolates from retail meat and offal. Kraken2

123 was used to confirm taxonomic classification and isolate purity 124 [\(https://pubmed.ncbi.nlm.nih.gov/31779668/](https://pubmed.ncbi.nlm.nih.gov/31779668/)); two isolates from two human cases were confirmed 125 as *C. lari* and were excluded from this analysis. *De novo* assembly of the genome sequence for each 126 isolate from sequencing reads was performed using SPAdes 127 [\(https://pubmed.ncbi.nlm.nih.gov/32559359/](https://pubmed.ncbi.nlm.nih.gov/32559359/)). The multi-locus sequence type (MLST) was 128 determined from each isolate using the MLST software (v2.19.0; [https://github.com/tseemann/mlst\)](https://github.com/tseemann/mlst) 129 and the PubMLST *Campylobacter jejuni/coli* database [28]. Isolate genome sequences were also 130 screened for resistance determinants using the abriTAMR pipeline (v1.0.7; [https://github.com/MDU-](https://github.com/MDU-PHL/abritamr)131 [PHL/abritamr](https://github.com/MDU-PHL/abritamr)) and the AMRFinderPLUS database (v3.10.16; 132 <https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/>). Virulence genes 133 present in each isolate genome sequence were detected using Abricate 134 [\(https://github.com/tseemann/abricate](https://aus01.safelinks.protection.outlook.com/?url=https://github.com/tseemann/abricate&data=05%7C01%7Cdanielle.cribb@anu.edu.au%7C661524e13b4c4568415908dbb29647e2%7Ce37d725cab5c46249ae5f0533e486437%7C0%7C0%7C638300131897171229%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0=%7C3000%7C%7C%7C&sdata=DbXSDcYo4VXQ158LKTX1KmNLuMJxxavmHdt8HZ9FJz0=&reserved=0)) with genes from the Virulence Factor Database (VFDB) [29]. 135 The parameters used for gene detection were the top hit with >80% gene coverage and >80% nucleic 136 acid sequence identity. Abricate was found to be unsuitable for detecting the *porA* and the *flaA* gene 137 in this set of isolates. The paralogous *flaA* and *flaB* genes caused assembly issues which resulted in 138 incomplete *flaA gene* assemblies. The peptide sequence 139 ADKAMDEQLKILDTIKTKATQAAQDGQSLKTRTM from near the N-terminus of FlaA was found to be 140 encoded in a contig from each assembly. Subsequently, the presence of the complete *flaA* and *flaB* 141 genes was inferred by mapping reads from each isolate to the *flaA* gene of *C. jejuni* strain NCTC11168. 142 For *porA,* a protein level detection using the PorA protein from *C. jejuni* strain NCTC11168 as the 143 subject for a blast search against the assembled genome of each isolate was used due to sequence 144 identity less than 80%. Core genome comparison of isolates within a species was performed using 145 Bohra [\(https://github.com/MDU-PHL/bohra](https://github.com/MDU-PHL/bohra)). The genome sequences of *C. jejuni* strain RM1221 146 (NC\_003912) and *C. coli* strain 76339 (NC\_022132) were used as reference genome sequences for the 147 *C. jejuni* and *C. coli* core genome comparisons respectively.

### 148 **Inference of antimicrobial resistance phenotype**

149 We used resistance genes and mutations to infer phenotypic resistance (Table S1) in agreement with 150 our previous phenotypic testing results [30]. We investigated chromosomal mutations in the *bla*<sub>OXA-61</sub> 151 promotor region*,* the 23S rRNA gene*,* and the quinolone resistance determining region of *gyrA*, as 152 previously described [27]. Ampicillin (AMP) resistance was inferred from a point mutation at position 153 57 in the *blaOXA-61* promotor region, associated with gene expression inactivation [31]. Resistance to 154 erythromycin (ERY) was determined based on the nucleotide at positions 2074 and 2075 of the 23S 155 rRNA gene [32]. Ciprofloxacin resistance (CIP) was determined by examining the amino acid at position 156 86 of GyrA (T86I confers resistance) [33]. The presence of the *tet*(O), aph(3')-IIIa, and *erm*(B) genes 157 inferred resistance to tetracycline (TET), gentamicin (GEN), and ERY, respectively [34-36]. We defined 158 multi-drug resistance (MDR) as displaying a resistant gene profile for three or more antimicrobial drug 159 classes [37]. Short-read WGS data for all isolates were deposited to the NCBI Sequence Read Archive 160 under bioprojects PRJNA592186, PRJNA560409, and PRJNA591966 161 [\(https://www.ncbi.nlm.nih.gov/sra](https://www.ncbi.nlm.nih.gov/sra)) (Table S2).

#### 162 **Virulence factor analysis**

163 We selected virulence genes that frequently occur in studies of genetic determinants of severe 164 campylobacteriosis in humans [8, 38-40]. We compared the prevalence of each virulence gene in each 165 *Campylobacter* species in Australia with pooled prevalence from a small collection of isolates from 166 international studies. We also assessed virulence genotype clustering and total gene count by MLST. 167 Additionally, we included the total number of virulence genes present in isolates as a categorical 168 predictor variable in generalised linear models described below. After excluding any genes that were 169 present or absent from all isolates, we used virulence genes to predict hospitalisation and long 170 diarrhoeal illness. Further, we compared virulence factors between food and case isolates to 171 determine if these factors predict human campylobacteriosis. We tested multiple predictive modelling 172 methods including random forest, logic regression, and binary discriminant analysis [41-44]. We

173 considered Kappa statistic values >0.3 to indicate that the chosen model performed substantially 174 better than naïve classification.

#### 175 **Statistical analysis**

176 All data analyses were performed with R (version 4.0.2) [45]. We used Pearson's chi square test and 177 Student's t-test to assess statistical differences between categorical variable groups and means (*p*  178 ≤0.05). We fitted a generalised additive model with a logit link to predict prevalence of symptoms and 179 hospitalisation as a smooth function of age [46]. We used generalised linear models to calculate 180 adjusted odds ratios (aORs) for demographic factors, medication use, health conditions and disease 181 profiles on the outcomes of hospitalisation, diarrhoeal disease lasting longer than seven days, and 182 antibiotic prescription following illness. We estimated aORs controlling for age group, gender, and 183 location, including any variables with a *p-*value ≤0.2 in a multivariable model. We used backward 184 stepwise logistic regression to identify variables for the final model (variables with *p*-values ≤0.05), 185 assessing significance, aORs and confidence intervals (CIs), and biological plausibility. We used ggplot2 186 to visualise all data figures, and used iToL (v5.0) for phylogenetic tree visualisation [47, 48].

#### 187 **Ethics**

188 This study was approved by the Australian National University Human Research Ethics Committee 189 (Ref. 2016/426), ACT Health Human Research Ethics Committee (Ref. ETH.8.17.168), Hunter New 190 England Human Research Ethics Committee (Ref. 17/08/4.03), Qld Health Human Research Ethics 191 Committee (Ref. RD007108), and the University of Melbourne Office of Research Ethics and Integrity 192 (Ref. 1750366.1).

## <sup>194</sup> **Results**

#### 195 **Symptom profiles and severity**

196 We included 571 cases from the ACT (*n* = 93), NSW (*n* = 178) and Qld (*n* = 300). The highest proportion 197 of cases (38.8%, 219/565) reported experiencing 11–20 loose bowel movements within a 24-hour 198 period with a mean length of illness of 7.5 days (standard deviation [*SD*] 4.9), generally increasing with 199 age from 6.4 days (*SD* 3.0) in 5–14-year-olds to 8.7 days (*SD* 9.6) in ≥75-year-olds. Case patients 200 reported an average of four symptoms in addition to diarrhoea, frequently including stomach cramps 201 (87.1%; 487/559), fever (75.6%; 428/566) and nausea (72.0%; 393/546). Case age influenced symptom 202 profiles, with symptoms such as stomach cramps, fever, headaches, and blood in stool less commonly 203 reported in older cases (Fig1a and 1b). The proportion of cases hospitalised was 24.9% (142/571), 204 which increased with age from 10.2% (5/49) of 0–4-year-olds to 45.0% (18/40) of ≥75-year-olds 205 (Fig1c). Overall, 49.8% (283/568) of case patients reported that they were prescribed antibiotics 206 following illness, with 59.3% (83/140) of hospitalised cases reporting antibiotic prescription compared 207 to 46.7% (200/428) of non-hospitalised cases (*p* = 0.01). Cases as young as 15 years old reported using 208 proton-pump inhibitors (PPIs), a medication prescribed to treat stomach acid-related gastro-209 oesophageal disorders and to prevent ulcers [49, 50]. Thirty percent (39/130) of 35–54-year-olds 210 reported using PPIs, increasing to 37.5% (15/40) in ≥75-year-olds. Symptom profiles were generally 211 similar between males and females. However, females were more likely to report stomach cramps 212 (91.1%, 216/237, *p* = 0.02) and nausea (80.7%, 188/233, *p* = 0.00) than males (84.2%, 271/322 and 213 65.5%, 205/313, respectively). There was no significant difference in the probability of hospitalisation 214 (25.5% [84/330] males, 24.1% [58/241] females) or duration of illness (7.4 days [*SD* 5.0] males, 7.6 215 days [*SD* 4.8] females). The mean VSS score was 10.7 (95% CI 5.7–15.7) (Fig 2). VSS scores were 216 influenced by age, with scores peaking in 15–34-year-olds (11.7, 95% CI 7.6–15.8) and tapering off in 217 older adults ≥75 years (8.8, 95% CI 4.0–13.6) (Fig 3).

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297105;](https://doi.org/10.1101/2023.10.16.23297105) this version posted October 17, 2023. The copyright holder for this

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 219 Fig 1. (a) Symptom profiles of Australian campylobacteriosis cases (muscle and body aches, nausea, and
- 220 stomach cramps), 2018–2019. (b) Symptom profiles of Australian campylobacteriosis cases (blood in stool,
- 221 fever, headache, and vomiting), 2018–2019. (c) Course of disease characteristics of Australian
- 222 campylobacteriosis cases (hospitalisation, hospitalisation ≥3 days, length of illness ≥7 days), 2018–2019. The
- 223 solid lines indicate estimated prevalence from a univariable generalised additive model with a logit link.<br>224 Shading around each line represents the 95% confidence interval for the prevalence estimate.
- Shading around each line represents the 95% confidence interval for the prevalence estimate.



perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297105;](https://doi.org/10.1101/2023.10.16.23297105) this version posted October 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

 Fig 2. Distribution of modified Vesikari Scoring System scores for 571 campylobacteriosis cases in Australia, 2018–2019. Bars represent the percentage of cases reporting the corresponding Vesikari Score. Error bars are calculated from binomial confidence intervals using the Pearson-Klopper exact method. Counts are provided

above the bar for each Vesikari Score.





 Fig 3. Distribution of modified Vesikari Scoring System scores by age for 571 campylobacteriosis cases in Australia, 2018–2019. The solid line indicates the estimated score from a generalised additive model with a

236 logit link. Shading around the line represents the 95% confidence interval for the score estimate.



239 We constructed three multivariable models, adjusting for age, sex, and location for the outcomes of 240 hospitalisation, antibiotic prescription, and duration of illness for cases with a sequenced 241 *Campylobacter* isolate (*n* = 506; Tables S3–S5). We found that vomiting (aOR 2.6, 95% CI 1.5–4.6) and 242 chronic gastrointestinal (GI) illness (e.g., Crohn's disease, irritable bowel syndrome, ulcerative colitis; 243 aOR 4.4, 95% CI 1.8–11.1) were associated with higher odds of hospitalisation (Table S3).

244 Factors associated with an increased odds of antibiotic prescription following illness included having 245 blood in stool (aOR 1.6, 95% CI 1.1–2.4), having diarrhoea lasting longer than seven days (aOR 2.0, 246 95% CI 1.3 – 2.9), and being hospitalised (aOR 1.9, 95% CI 1.1–3.2) (Table S4). Factors associated with 247 increased odds of diarrhoeal disease lasting longer than seven days included having headaches (aOR 248 1.7, 95% CI 1.1–2.6) and taking proton pump inhibitors (PPIs) (aOR 2.0, 95% CI 1.2–3.3) (Table S5). We 249 found a cyclical relationship between hospitalisation, length of illness, and antibiotic prescription 250 following illness with these factors showing as significant in each model. We chose to report the most 251 biologically plausible pathways.

#### 252 **Genetic diversity of clinical isolates**

253 We included 422 *C. jejuni* and 84 *C. coli* isolates derived from human clinical samples in this study. *C.*  254 *jejuni* isolates were assigned to 65 unique MLSTs while *C. coli* isolates were assigned to 21 (Table S6). 255 The most common sequence types detected were ST50 for *C. jejuni* (17.8%, 75/422), and ST1181 for 256 *C. coli* (27.4%, 23/84) (Table S6; S1 and S2 Figs). Pairwise core genome single nucleotide polymorphism 257 (SNP) distances between *C. jejuni* isolates ranged from zero to ~37k SNPs, while *C. coli* isolates ranged 258 from zero to ~82k SNPs.

#### 259 **Antimicrobial resistance genes**

260 We detected antimicrobial resistance (AMR) genes and point mutations in 20.4% (103/506) of the 261 human isolates, with MDR genotype profiles in 0.04% (2/506) of isolates (Fig 4, S3 Fig, S4 Fig). Results 262 for resistance determinants in the food isolates are reported elsewhere [27]. We did not detect AMP 263 or CIP genomic resistance genes or mutations in one *C. jejuni* and 21 *C. coli* isolates, although this was

264 not tested phenotypically. The most common resistant mechanism detected was for CIP with 12.3% 265 (62/505) of isolates (*C. jejuni* 13.1% [55/421], *C. coli* 8.3% [7/84]) and for TET at 9.7% (49/506) of 266 isolates (*C. jejuni* 11.1% [47/422], *C. coli* 2.4% [2/84]). An AMP resistant genotype was detected in 267 5.2% (25/485) of isolates (*C. jejuni* 5.7% [24/422], *C. coli* 1.6% [1/63]), with isolates possessing the 268 *blaOXA-184* gene (*n* = 3) or a *blaOXA-61* gene and active promotor (*n* = 22; a point mutation at position 57 269 in the promotor regulates gene expression). A GEN resistant genotype was present in 0.4% (2/506) of 270 isolates (*C. jejuni* 0.2% [1/422], *C. coli* 1.2% [1/84]), and ERY resistant genotype was present in 0.2% 271 (1/506) of isolates (not detected in *C. jejuni*, 1.2% [1/84] in *C. coli*), possessing the 23S rRNA A2075G 272 mutation. Two isolates were inferred to be MDR: one *C. coli* isolate harboured five antimicrobial 273 determinants (AMP, CIP, ERY, GEN, and TET) and one *C. jejuni* isolate harboured four (AMP, CIP, GEN, 274 and TET).

 Fig 4. Genotypic antimicrobial resistance profiles of 506 *Campylobacter* isolates for ampicillin (AMP), ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), and tetracycline (TET). Isolates were classified as susceptible if they did not possess a known resistance gene or mutation (*n* = 403). The number of isolates 278 possessing each resistance profile is noted above the respective bar. Error bars are calculated from binomial confidence intervals using the Pearson-Klopper exact method.



### 281 **Virulence factors**

282 Human clinical *C. jejuni* isolates had a median of 96 virulence genes detected (range 82–118) and *C.*  283 *coli* isolates had a median of 72 genes (range 64–86). Two-thirds of screened genes were highly 284 conserved (≥95% present) across isolates in both species, with 68.1% (81/119) for *C. jejuni,* and 68.7% 285 (68/99) for *C. coli*. The *flaA, flaB,* and *porA* genes were present in all isolates through additional 286 screening. We detected virulence gene clustering by MLST (Table S6; S1 Fig; S2 Fig). Further, 14 of 19 287 and nine of 12 virulence genes selected for international comparison for *C. jejuni*, and *C. coli,*  288 respectively, were highly conserved across isolates, particularly those associated with adhesion and 289 colonisation (e.g., *cadF, porA,* and *pebA*), motility (e.g., *flaA*), cytotoxin production (e.g., *cdtABC*), and 290 invasiveness (e.g., *ciaBC* and *flaC*) (Table 2). Genes associated with immune modulation (e.g., *cstIII* and 291 *neuABC*) were present variably across *C. jejuni* isolates at approximately 35.0%. These genes were rare 292 or absent in *C. coli* isolates. Lipooligosaccharide (LOS) and capsule gene screening was limited to those 293 genes present in *C. jejuni* NCTC 11168.

294 We compared all virulence genes present in either our human isolates and 285 *C. jejuni* and 331 *C. coli*  295 isolates from meat and offal. Virulence gene *pseE/maf5* was more common in *C. jejuni* food isolates 296 than in case isolates while *Cj1421c, Cj1422c, kpsC, rbfC, fliK, Cj1136, Cj1138, waaV,* and *wlaN* were 297 more common in *C. jejuni* case isolates (Table S7). No isolates significantly differed between food and 298 human isolates for *C. coli.* We did not observe an association between the total number of virulence 299 genes present and the odds of longer duration of diarrhoeal illness, hospitalisation, or antibiotic 300 prescription following illness (Tables S3–S5). Random forest analyses of 58 *C. jejuni* and 43 *C. coli*  301 virulence genes with less than 100.0% prevalence across isolates did not detect any individual or 302 specific combinations of virulence genes that predicted severe illness or hospitalisation, nor did 303 analysis of 72 *C. coli* genes comparing campylobacteriosis case isolates with food isolates (Kappa <0.3) 304 (S1 and S2 File). Analysis of 65 *C. jejuni* virulence genes comparing case and food isolates highlighted

305 that some virulence genes such as *fliK, Cj1138,* and *Cj1136* were enriched in isolates from humans

306 (Kappa 0.51) (S5 Fig).





\* prevalence of international isolates sourced from international studies [8, 38-40, 51-55]. The point estimate is calculated across all isolates. The range is reported highest and lowest prevalence in the included studies. '–' gene was not screened or reported. † *flaA* gene prevalence in Australia determined from presence of amino acids due to *flaA/flaB* paralog interference at nucleotide sequence level. ‡ *porA* gene prevalence in Australia determined from presence of amino acids due to low read quality.

## <sup>309</sup> **Discussion**

310 Campylobacteriosis cases in Australia displayed relatively similar disease profiles, although 311 some cases experienced more severe symptoms and outcomes, and *Campylobacter* isolates showed 312 considerable variation in their genome, as in many geographic regions [8]. We found *in silico* AMR 313 determinants in one-fifth of human clinical isolates, with very few isolates possessing MDR genotypes. 314 Many putative virulence genes were highly conserved across patient case and retail meat isolates, 315 suggesting these may be central to the pathogen's fitness regardless of the ability to cause disease. 316 Others, including those associated with immune modulation in microbiological studies, were far less 317 conserved or even rare in human and food isolates, reflecting their less essential role in *Campylobacter*  318 viability [56]. We did not identify any associations between individual or combinations of virulence 319 genes and severe disease characteristics. However, we did detect an association between certain 320 genes and *C. jejuni* case isolates compared with food isolates, namely *fliK, Cj1136,* and *Cj1138*.

321 The spectrum of health outcomes from *Campylobacter* infections is complex, but host factors 322 including age, comorbidities, and medication use likely play an important determining role [57]. While 323 cases aged between 15 and 34 years were more likely to report a higher modified VSS score, older 324 cases had higher odds of being hospitalised. A previous study systematically describing acute 325 gastroenteritis symptoms by age group similarly found that older adults were more likely to be 326 hospitalised and have severe illness, but reported symptoms decreased with age [58]. A hospital-327 based data linkage study in Australia reported that comorbidities were present in 34.5% of cases, and 328 that hospitalisation rates noticeably increased among patients aged over 60 years [57]. These studies 329 also found increases in invasive infection, hospitalisation, length of illness and mortality accompanied 330 increasing age [57, 58]. Other factors beyond traditional symptoms of gastroenteritis may be more 331 likely to result in hospitalisation for older cases, such as dehydration or loss of appetite [13, 58]. Our 332 study found that over 30% of cases aged ≥35-years-old had used PPIs prior to illness and that use was 333 associated with longer duration of diarrhoea. This is consistent with a data linkage study that found

334 that PPI use was significantly associated with infectious gastroenteritis hospitalisation [50]. While PPIs 335 are considered a safe and effective medication, approved for long-term use, many patients are 336 unaware of the increased risks of infectious gastrointestinal illness and subsequent hospitalisation 337 that may accompany their use. While certain symptoms may indicate a need for hospitalisation, the 338 overall severity of disease does not necessarily predict hospitalisation. Instead, the age of a case is the 339 most significant determinant of the symptoms they experience and their need for seeking healthcare.

340 While previous genomic epidemiological studies have explored the role of virulence factors in 341 campylobacteriosis, we did not detect any direct relationship between human clinical disease 342 outcomes and the presence of individual virulence genes, combinations of virulence genes, or total 343 number of virulence genes [16, 59]. However, random forest analysis of *C. jejuni* isolates found genes 344 associated with the flagellar hook length gene (*fliK*) and LOS synthesis (*Cj1136* and *Cj1138*) to be more 345 prevalent in case than food isolates. As food is the primary vehicle for *Campylobacter* this finding 346 suggests these genes are important for exposure to translate into clinical disease [60, 61]. 347 *Campylobacter* have developed a symbiotic relationship with avian and mammalian species [62]. 348 There are likely to be a range of genes and gene combinations that have developed to maintain this 349 relationship. Additionally, poultry hosts carry a wide variety of *Campylobacter* as part of their normal 350 flora; genes curated for symbiosis in poultry may cause disease in humans.

351 Animal models have been used to study *Campylobacter* virulence, but current models are 352 unable to successfully reproduce diarrhoeal illness seen in humans [63-65]. Due to this lack of a 353 suitable animal model, understanding *Campylobacter* virulence mechanisms remains limited. 354 Nevertheless, expression of factors associated with pathogen motility, adhesion, invasion, and toxin 355 production may play a role in *Campylobacter* infection [17, 54, 66, 67]. In this study, the *flhA* and *flaA*  356 genes associated with motility were highly conserved across both *C. jejuni* and *C. coli* isolates, 357 consistent with previous findings [19, 38, 54]. Genes associated with adhesion and colonisation of 358 epithelial cells (i.e., *cadF, jlpA, porA,* and *pebA*) were also highly conserved in our study isolates and in

359 those investigated previously [38, 52, 54, 55]. In particular, the *cadF* gene is considered an essential 360 gene for adhesion to intestinal cells during the initial stages of campylobacteriosis [17, 52, 54]. 361 Similarly, the presence of the *ciaB* and *flaC* genes are considered critical for the invasion of epithelial 362 cells [66]. However, our study results indicate that even in the absence of *ciaB,* clinical disease can 363 occur.

364 Cytolethal distending toxin (CDT) is a commonly distributed toxin across Gram-negative 365 bacteria (e.g., *Shigella* and *Escherichia coli*) and is well characterised in *Campylobacter* spp. [18, 59]. 366 CDT operates by promoting intestinal epithelial cell damage and death and is implicated in severe 367 illness caused by *C. jejuni* [19, 68, 69]. Previous studies have suggested that all three gene subunits of 368 the *cdtABC* operon are required for full toxin function [70-72]. Global prevalence of the *cdtABC* operon 369 is high in *C. jejuni* strains but is variable in *C. coli* strains; the *cdtABC* genes were absent in the *C. coli*  370 isolates in our study and ranged from ~13% to 100% across international studies. A previous study 371 found gene differences between *Campylobacter* species, attributing this to a reliance on *C. jejuni*-372 focused research for understanding virulence [40]. We detected high prevalence of the *cdtABC* operon 373 in *C. jejuni* isolates in our study (>99%), but a previous study comparing diarrhoeal and non-diarrhoeal 374 campylobacteriosis cases detected a much lower prevalence of 76.5% in the non-diarrhoeal cases, 375 indicating that this gene cluster may play a role in development of diarrhoea [8].

376 The functions of individual genes associated with the LOS (i.e., *htrB, waaC, cstIII, wlaN,*  377 *neuABC*) are not well defined, but are thought to be implicated in the development of Guillain-Barré 378 syndrome (GBS), an immunoreactive condition where nervous system receptors are targeted and 379 damaged by the host immune response [39]. The function of these genes is to sialyate *Campylobacter*  380 LOS on the surface of *C. jejuni* cells, mimicking sialyation on gangliosides found on human peripheral 381 nerve cells; this molecular mimicry can trigger GBS [73, 74]. The *wlaN, cstIII* and *neuABC* genes were 382 present in approximately one third of *C. jejuni* isolates and were mostly absent in *C. coli*. Further

383 investigation is needed to elucidate the relationship between the expression of these genes and 384 development of GBS.

385 In our previously published Australian study of *Campylobacter* genomics, we reported that 386 the prevalence of AMR determinants was low in *Campylobacter* isolates compared to other high-387 income countries [30]. Here, we observed a high rate of antibiotic use following infection, regardless 388 of hospitalisation status, length of illness, or case age. Australian prescription guidelines recommend 389 the use of azithromycin, CIP, or norfloxacin for those with severe disease or in vulnerable groups [75]. 390 While AMR is low in Australia, attributed to regulations on the prescription of quinolones in humans 391 and food-producing animals [76], growing levels of AMR is a global issue and antimicrobial 392 stewardship is a priority for public health. High prescription rates should be investigated further to 393 ensure optimal patient care while combating antibiotic resistance. Previous studies have examined 394 relationships between virulence markers and AMR [38, 66, 72], with one study reporting a relationship 395 between resistance to fluoroquinolones and TET and the presence of the *virB11* and *wlaN* genes [38] 396 and another with resistance to TET or ERY and *cdtA* and *dnaJ* genes [72]. We observed some clustering 397 of AMR genes by sequence type but did not identify any relationships between AMR and virulence 398 genes or severe disease outcomes.

399 Our study cases were recruited from among cases notified to a health department, meaning 400 that all cases experienced symptomatic illness requiring care and therefore mild or asymptomatic 401 cases were unlikely to have been recruited [10, 25]. Further, cases from the ACT and NSW were largely 402 recruited from hospital-based laboratory service samples suggesting that our hospitalisation rate is 403 not representative of the general hospitalisation rate for campylobacteriosis. An ACT-based study 404 estimated that 13.6% of campylobacteriosis cases were hospitalised, increasing to 20.0% when non-405 admitted emergency department visits were included [57]. We relied on self-reported symptoms from 406 cases, which may be less reliable than a clinical assessment by a healthcare professional. Some 407 symptoms can be subjective and may not be accurately reported (e.g., fever) or respondents may be

408 reluctant to report them. Older respondents and those with poorer memory or pre-existing health 409 conditions may have experienced issues with recall, particularly when asked about specific symptoms, 410 resulting in recall bias. Finally, we explored a subset of known putative virulence-associated genes 411 sourced from the VFDB. This was not a comprehensive list and did not explore all virulence genes 412 noted in the literature. We included a small number of studies and isolates in our international gene 413 comparison, which is unlikely to be representative of global gene prevalence. As research into 414 virulence determinants continues, further genes and gene combinations should be explored to 415 understand their role in disease.

416 In this study, we did not find direct associations between genetic markers of virulence and 417 disease outcomes for *Campylobacter.* However, we did detect associations between certain virulence 418 genes and human *C. jejuni* isolates compared with food isolates. Our study provides valuable insights 419 into the genomic diversity, the prevalence of virulence markers, and the low prevalence of antibiotic 420 resistance among *Campylobacter* isolates. To continue uncovering unknown aspects of the pathogen, 421 *Campylobacter* surveillance should continue to incorporate WGS to provide high-resolution data, 422 particularly for developing baseline estimates of genomic characteristics in mild, moderate, and 423 severe disease to understand associations with severity. To support this, researchers conducting 424 cohort studies should consider examining virulence factor prevalence between symptomatic and 425 asymptomatic cases, as well as the development of more severe sequelae such as GBS in cases. Future 426 studies in Australia should follow international studies that have investigated the presence or absence 427 of certain virulence genes, AMR, and the molecular relationships between human clinical and source 428 isolates to enable a more comprehensive understanding of the pathogenesis of campylobacteriosis 429 [38, 77, 78].

430

## <sup>432</sup> **Acknowledgements**

433 The authors would like to thank the extended CampySource Project team, reference panel, and 434 additional contributors to the study. The CampySource Project team comprises three working groups 435 and a reference panel. The working groups focus on food and animal sampling, epidemiology and 436 modelling, and genomics. The reference panel includes expert representatives from government and 437 industry. The study includes the following partner organisations: the Australian National University, 438 Massey University, University of Melbourne, Queensland Health, Queensland Health Forensic and 439 Scientific Services, New South Wales Food Authority, New South Wales Health, Hunter New England 440 Health, Victorian Department of Health and Human Services, Food Standards Australia New Zealand, 441 Commonwealth Department of Health and AgriFutures Australia–Chicken Meat Program. 442 CampySource also collaborates with the following organisations: ACT Health, Sullivan Nicolaides 443 Pathology, University of Queensland, Primary Industries and Regions South Australia, Department of 444 Health and Human Services Tasmania, Meat and Livestock Australia, and New Zealand Ministry for 445 Primary Industries.

446 The CampySource Project Team consists of: Nigel P French, Massey University, New Zealand; Mary 447 Valcanis, The University of Melbourne; Dieter Bulach, The University of Melbourne; Emily Fearnley, 448 South Australian Department for Health and Wellbeing; Russell Stafford, Queensland Health; Amy 449 Jennison, Queensland Health; Trudy Graham, Queensland Health; Keira Glasgow, Health Protection 450 NSW; Kirsty Hope, Health Protection NSW; Themy Saputra, NSW Food Authority; Craig Shadbolt, NSW 451 Food Authority; Arie Havelaar, The University of Florida, USA; Joy Gregory, Department of Health and 452 Human Services, Victoria; James Flint, Hunter New England Health; Simon Firestone, The University of 453 Melbourne; James Conlan, Food Standards Australia New Zealand; Ben Daughtry, Food Standards 454 Australia New Zealand; James J Smith, Queensland Health; Heather Haines, Department of Health and 455 Human Services, Victoria; Sally Symes, Department of Health and Human Services, Victoria; Barbara 456 Butow, Food Standards Australia New Zealand; Liana Varrone, The University of Queensland; Linda 457 Selvey, The University of Queensland; Tim Sloan-Gardner, ACT Health; Deborah Denehy, ACT Health;

458 Radomir Krsteski, ACT Health; Natasha Waters, ACT Health; Kim Lilly, Hunter New England Health; 459 Julie Collins, Hunter New England Health; Tony Merritt, Hunter New England Health; Rod Givney, 460 Hunter New England Health; Joanne Barfield, Hunter New England Health; Ben Howden, The 461 University of Melbourne; Kylie Hewson, AgriFutures Australia–Chicken Meat Program; Dani Cribb, The 462 Australian National University; Rhiannon Wallace, The Australian National University; Angus McLure, 463 The Australian National University; Ben Polkinghorne, The Australian National University; Cameron 464 Moffatt, The Australian National University; Martyn Kirk, The Australian National University; and 465 Kathryn Glass, The Australian National University.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297105;](https://doi.org/10.1101/2023.10.16.23297105) this version posted October 17, 2023. The copyright holder for this

It is made available under a CC-BY 4.0 International license.

## <sup>466</sup> **References**

- 467 1. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global Epidemiology of 468 *Campylobacter* Infection. Clin Microbiol Rev. 2015;28(3):687-720. doi: 10.1128/CMR.00006- 469 15. PubMed PMID: 26062576.
- 470 2. Australian Government Department of Health and Aged Care. National Notifiable Disease 471 Surveillance System - National Communicable Disease Surveillance Dashboard 2023. 472 Available from: https://nindss.health.gov.au/pbi-dashboard/.
- 473 3. European Food Safety Authority, European Centre for Disease Prevention and Control. The 474 European Union One Health 2019 Zoonoses Report. EFSA J. 2021;19(2):e06406. doi: 475 10.2903/j.efsa.2021.6406.
- 476 4. Centers for Disease Control and Prevention. FoodNet Fast Pathogen Surveillance 2022 477 [cited 2023 February]. Available from: cdc.gov/foodnetfast/.
- 478 5. Varrone L, Glass K, Stafford RJ, Kirk MD, Selvey L, CampySource Project Team. A meta-479 analysis of case-control studies examining sporadic campylobacteriosis in Australia and New 480 Zealand from 1990 to 2016. Aust N Z J Public Health. 2020;44(4):313-9. doi: 481 https://doi.org/10.1111/1753-6405.12998.
- 482 6. Cribb DM, Varrone L, Wallace RL, McLure AT, Smith JJ, Stafford RJ, et al. Risk factors for 483 campylobacteriosis in Australia: outcomes of a 2018–2019 case–control study. BMC Infect 484 Dis. 2022;22(1):586. doi: 10.1186/s12879-022-07553-6.
- 485 7. Acheson D, Allos BM. Campylobacter jejuni Infections: Update on Emerging Issues and 486 Trends. Clinical Infectious Diseases. 2001;32(8):1201-6. doi: 10.1086/319760.
- 487 8. Wysok B, Wojtacka J, Hänninen M-L, Kivistö R. Antimicrobial Resistance and Virulence-488 Associated Markers in Campylobacter Strains From Diarrheic and Non-diarrheic Humans in 489 Poland. Frontiers in Microbiology. 2020;11. doi: 10.3389/fmicb.2020.01799.
- 490 9. Wieczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. Biomed 491 Res Int. 2013;2013:340605. Epub 2013/07/19. doi: 10.1155/2013/340605. PubMed PMID: 492 23865047; PubMed Central PMCID: PMCPMC3707206.
- 493 10. Elnegaard S, Andersen RS, Pedersen AF, Larsen PV, Søndergaard J, Rasmussen S, et al. Self-494 reported symptoms and healthcare seeking in the general population--exploring "The 495 Symptom Iceberg". BMC Public Health. 2015;15:685. Epub 2015/07/22. doi:
- 496 10.1186/s12889-015-2034-5. PubMed PMID: 26195232; PubMed Central PMCID: 497 PMCPMC4509464.
- 498 11. McAteer A, Elliott AM, Hannaford PC. Ascertaining the size of the symptom iceberg in a UK-499 wide community-based survey. Br J Gen Pract. 2011;61(582):e1-11. Epub 2011/03/16. doi: 500 10.3399/bjgp11X548910. PubMed PMID: 21401979; PubMed Central PMCID: 501 PMCPMC3020067.
- 502 12. Gillespie IA, apos, Brien SJ, Frost JA, Tam C, Tompkins D, et al. Investigating vomiting and/or 503 bloody diarrhoea in Campylobacter jejuni infection. Journal of Medical Microbiology. 504 2006;55(6):741-6. doi: https://doi.org/10.1099/jmm.0.46422-0.
- 505 13. Hall G, Kirk M, Ashbolt R, Gregory J, Lalor K, Millard G, et al. Results from the National 506 Gastroenteritis Survey 2001 - 2002. National Centre for Epidemiology and Population Health, 507 The Australian National University, 2004.
- 508 14. Wallace RL, Cribb DM, Bulach DM, Ingle DJ, Joensen KG, Nielsen EM, et al. Campylobacter 509 jejuni ST50, a pathogen of global importance: A comparative genomic analysis of isolates 510 from Australia, Europe and North America. Zoonoses and Public Health. 2021;68(6):638-49. 511 doi: https://doi.org/10.1111/zph.12853.
- 512 15. Djeghout B, Bloomfield SJ, Rudder S, Elumogo N, Mather AE, Wain J, et al. Comparative 513 genomics of Campylobacter jejuni from clinical campylobacteriosis stool specimens. Gut 514 Pathogens. 2022;14(1):45. doi: 10.1186/s13099-022-00520-1.
- 515 16. Dasti JI, Tareen AM, Lugert R, Zautner AE, Groß U. Campylobacter jejuni: A brief overview on 516 pathogenicity-associated factors and disease-mediating mechanisms. International Journal

It is made available under a CC-BY 4.0 International license.



perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297105;](https://doi.org/10.1101/2023.10.16.23297105) this version posted October 17, 2023. The copyright holder for this

It is made available under a CC-BY 4.0 International license.

567 30. Wallace R, Bulach D, McLure A, Varrone L, Jennison A, Valcanis M, et al. Antimicrobial 568 Resistance of *Campylobacter* spp. Causing Human Infection in Australia: An International 569 Comparison. Microb Drug Resist. 2021;27(4):518-28. doi: 10.1089/mdr.2020.0082. PubMed 570 PMID: 32898460. 571 31. Zeng X, Brown S, Gillespie B, Lin J. A single nucleotide in the promoter region modulates the 572 expression of the β-lactamase OXA-61 in Campylobacter jejuni. J Antimicrob Chemother. 573 2014;69(5):1215-23. Epub 2014/01/11. doi: 10.1093/jac/dkt515. PubMed PMID: 24408987. 574 32. Ladely SR, Meinersmann RJ, Englen MD, Fedorka-Cray PJ, Harrison MA. 23S rRNA gene 575 mutations contributing to macrolide resistance in Campylobacter jejuni and Campylobacter 576 coli. Foodborne Pathog Dis. 2009;6(1):91-8. Epub 2008/11/19. doi: 10.1089/fpd.2008.0098. 577 PubMed PMID: 19014274. 578 33. Hakanen A, Jalava J, Kotilainen P, Jousimies-Somer H, Siitonen A, Huovinen P. gyrA 579 polymorphism in Campylobacter jejuni: detection of gyrA mutations in 162 C. jejuni isolates 580 by single-strand conformation polymorphism and DNA sequencing. Antimicrob Agents 581 Chemother. 2002;46(8):2644-7. Epub 2002/07/18. doi: 10.1128/aac.46.8.2644-2647.2002. 582 PubMed PMID: 12121947; PubMed Central PMCID: PMCPMC127378. 583 34. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 584 2010;13(6):151-71. Epub 2010/09/14. doi: 10.1016/j.drup.2010.08.003. PubMed PMID: 585 20833577; PubMed Central PMCID: PMCPMC2992599. 586 35. Whitehouse CA, Young S, Li C, Hsu CH, Martin G, Zhao S. Use of whole-genome sequencing 587 for Campylobacter surveillance from NARMS retail poultry in the United States in 2015. Food 588 Microbiol. 2018;73:122-8. Epub 2018/03/13. doi: 10.1016/j.fm.2018.01.018. PubMed PMID: 589 29526197. 590 36. Qin S, Wang Y, Zhang Q, Zhang M, Deng F, Shen Z, et al. Report of ribosomal RNA methylase 591 gene erm(B) in multidrug-resistant Campylobacter coli. J Antimicrob Chemother. 592 2014;69(4):964-8. Epub 2013/12/18. doi: 10.1093/jac/dkt492. PubMed PMID: 24335515. 593 37. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-594 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert 595 proposal for interim standard definitions for acquired resistance. Clinical Microbiology and 596 Infection. 2012;18(3):268-81. doi: https://doi.org/10.1111/j.1469-0691.2011.03570.x. 597 38. Wieczorek K, Wołkowicz T, Osek J. Antimicrobial Resistance and Virulence-Associated Traits 598 of Campylobacter jejuni Isolated From Poultry Food Chain and Humans With Diarrhea. 599 Frontiers in Microbiology. 2018;9. doi: 10.3389/fmicb.2018.01508. 600 39. Quino W, Caro-Castro J, Hurtado V, Flores-León D, Gonzalez-Escalona N, Gavilan RG. 601 Genomic Analysis and Antimicrobial Resistance of Campylobacter jejuni and Campylobacter 602 coli in Peru. Frontiers in Microbiology. 2022;12. doi: 10.3389/fmicb.2021.802404. 603 40. Bravo V, Katz A, Porte L, Weitzel T, Varela C, Gonzalez-Escalona N, et al. Genomic analysis of 604 the diversity, antimicrobial resistance and virulence potential of clinical Campylobacter jejuni 605 and Campylobacter coli strains from Chile. PLoS Negl Trop Dis. 2021;15(2):e0009207. Epub 606 2021/02/20. doi: 10.1371/journal.pntd.0009207. PubMed PMID: 33606689; PubMed Central 607 PMCID: PMCPMC7928456. 608 41. Breinman L, Cutler A, Liaw A, Wiener M. randomForest: Breiman and Cutler's Random 609 Forests for Classification and Regression 2022. Available from: https://cran.r-610 project.org/web/packages/randomForest/index.html. 611 42. Kuhn M, Wing J, Weston S, Williams A, Keefer C, Engelhardt A, et al. caret: Classification and 612 Regression Training 2023. Available from: https://cran.r-project.org/web/packages/caret/. 613 43. Kooperberg C, Ruczinski I. LogicReg: Logic Regression. 2022. 614 44. Gibb S, Strimmer K. binda: Multi-Class Discriminant Analysis using Binary Predictors 2021. 615 Available from: https://cran.r-project.org/web/packages/binda/index.html. 616 45. R Core Team. R: A language and environment for statistical computing. R Foundation for 617 Statistical Computing. Vienna, Austria Available from: https://www.R-project.org/.

618 46. Wood S. mgcv: Mixed GAM Computation Vehicle with Automatic Smoothness Estimation 619 2023. Available from: https://cran.r-project.org/web/packages/mgcv/index.html. 620 47. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree 621 display and annotation. Nucleic Acids Research. 2021;49(W1):W293-W6. doi: 622 10.1093/nar/gkab301. 623 48. Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, et al. ggplot2: Create 624 Elegant Data Visualisations Using the Grammar of Graphics 2023. Available from: 625 https://cran.r-project.org/web/packages/ggplot2/index.html. 626 49. Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton 627 pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749-56. Epub 628 2015/12/30. doi: 10.1136/gutjnl-2015-310861. PubMed PMID: 26719299. 629 50. Chen Y, Liu B, Glass K, Du W, Banks E, Kirk M. Use of Proton Pump Inhibitors and the Risk of 630 Hospitalization for Infectious Gastroenteritis. PloS one. 2016;11(12):e0168618-e. doi: 631 10.1371/journal.pone.0168618. PubMed PMID: 27997598. 632 51. González-Hein G, Huaracán B, García P, Figueroa G. Prevalence of virulence genes in strains 633 of Campylobacter jejuni isolated from human, bovine and broiler. Braz J Microbiol. 634 2013;44(4):1223-9. Epub 2014/04/02. doi: 10.1590/s1517-83822013000400028. PubMed 635 PMID: 24688515; PubMed Central PMCID: PMCPMC3958191. 636 52. Biswas D, Hannon SJ, Townsend HG, Potter A, Allan BJ. Genes coding for virulence 637 determinants of Campylobacter jejuni in human clinical and cattle isolates from Alberta, 638 Canada, and their potential role in colonization of poultry. Int Microbiol. 2011;14(1):25-32. 639 Epub 2011/10/22. doi: 10.2436/20.1501.01.132. PubMed PMID: 22015699. 640 53. Lluque A, Riveros M, Prada A, Ochoa TJ, Ruiz J. Virulence and Antimicrobial Resistance in 641 Campylobacter spp. from a Peruvian Pediatric Cohort. Scientifica (Cairo). 642 2017;2017:7848926. Epub 2017/11/14. doi: 10.1155/2017/7848926. PubMed PMID: 643 29130018; PubMed Central PMCID: PMCPMC5654289. 644 54. Casabonne C, Gonzalez A, Aquili V, Subils T, Balague C. Prevalence of Seven Virulence Genes 645 of Campylobacter jejuni Isolated from Patients with Diarrhea in Rosario, Argentina. 646 2016;3(4):e37727. Epub 2016-08-01. doi: 10.17795/iji-37727. 647 55. Kim JS, Lee MY, Kim SJ, Jeon S-E, Cha I, Hong S, et al. High-Level Ciprofloxacin-Resistant 648 Campylobacter jejuni Isolates Circulating in Humans and Animals in Incheon, Republic of 649 Korea. Zoonoses and Public Health. 2016;63(7):545-54. doi: 650 https://doi.org/10.1111/zph.12262. 651 56. Marsden GL, Li J, Everest PH, Lawson AJ, Ketley JM. Creation of a Large Deletion Mutant of 652 <i>Campylobacter jejuni</i> Reveals that the Lipooligosaccharide Gene Cluster Is Not 653 Required for Viability. Journal of Bacteriology. 2009;191(7):2392-9. doi: 654 doi:10.1128/jb.01397-08. 655 57. Moffatt CRM, Kennedy KJ, Selvey L, Kirk MD. Campylobacter-associated hospitalisations in 656 an Australian provincial setting. BMC Infectious Diseases. 2021;21(1):10. doi: 657 10.1186/s12879-020-05694-0. 658 58. White AE, Ciampa N, Chen Y, Kirk M, Nesbitt A, Bruce BB, et al. Characteristics of 659 Campylobacter and Salmonella Infections and Acute Gastroenteritis in Older Adults in 660 Australia, Canada, and the United States. Clin Infect Dis. 2019;69(9):1545-52. Epub 661 2019/01/03. doi: 10.1093/cid/ciy1142. PubMed PMID: 30602004; PubMed Central PMCID: 662 PMCPMC6606397. 663 59. Quetz JdS, Lima IFN, Havt A, Prata MMG, Cavalcante PA, Medeiros PHQS, et al. 664 Campylobacter jejuni infection and virulence-associated genes in children with moderate to 665 severe diarrhoea admitted to emergency rooms in northeastern Brazil. Journal of Medical 666 Microbiology. 2012;61(4):507-13. doi: https://doi.org/10.1099/jmm.0.040600-0. 667 60. Kamal N, Dorrell N, Jagannathan A, Turner SM, Constantinidou C, Studholme DJ, et al. 668 Deletion of a previously uncharacterized flagellar-hook-length control gene fliK modulates





719 Guillain-Barré and Miller Fisher Syndromes. Infection and Immunity. 2007;75(3):1245-54. 720 doi: doi:10.1128/IAI.00872-06. 721 75. Therapeutic Guidelines Limited. Acute infectious diarrhoea 2022 [cited 2023 26 June]. 722 Available from: 723 https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=ac 724 ute-gastroenteritis&guidelinename=Antibiotic&sectionId=toc\_d1e521#toc\_d1e521. 725 76. Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone 726 resistance through successful regulation, Australia. Emerg Infect Dis. 2012;18(9):1453-60. 727 doi: 10.3201/eid1809.111515. PubMed PMID: 22932272; PubMed Central PMCID: 728 PMCPMC3437704. 729 77. Andrzejewska M, Grudlewska-Buda K, Śpica D, Skowron K, Ćwiklińska-Jurkowska M, Szady-730 Grad M, et al. Genetic relatedness, virulence, and drug susceptibility of Campylobacter 731 isolated from water and wild birds. Frontiers in Cellular and Infection Microbiology. 2022;12. 732 doi: 10.3389/fcimb.2022.1005085.

- 733 78. Wysok B, Wojtacka J, Kivistö R. Pathogenicity of Campylobacter strains of poultry and human 734 origin from Poland. International Journal of Food Microbiology. 2020;334:108830. doi:
- 735 https://doi.org/10.1016/j.ijfoodmicro.2020.108830.

736

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297105;](https://doi.org/10.1101/2023.10.16.23297105) this version posted October 17, 2023. The copyright holder for this

#### It is made available under a CC-BY 4.0 International license.

## **Figure captions**

- **Fig 1. (a) Symptom profiles of Australian campylobacteriosis cases (muscle and body aches,**
- **nausea, and stomach cramps), 2018–2019. (b) Symptom profiles of Australian campylobacteriosis**
- **cases (blood in stool, fever, headache, and vomiting), 2018–2019. (c) Course of disease**
- **characteristics of Australian campylobacteriosis cases (hospitalisation, hospitalisation ≥3 days,**
- **length of illness ≥7 days), 2018–2019**. The solid lines indicate estimated prevalence from a
- 744 univariable generalised additive model with a logit link. Shading around each line represents the 95%
- 745 confidence interval for the prevalence estimate.
- **Fig 2. Distribution of modified Vesikari Scoring System scores for 571 campylobacteriosis cases in**
- **Australia, 2018–2019.** Bars represent the percentage of cases reporting the corresponding Vesikari
- 748 Score. Error bars are calculated from binomial confidence intervals using the Pearson-Klopper exact
- 749 method. Counts are provided above the bar for each Vesikari Score.
- **Fig 3. Distribution of modified Vesikari Scoring System scores by age for 571 campylobacteriosis**
- **cases in Australia, 2018–2019.** The solid line indicates the estimated score from a generalised
- 752 additive model with a logit link. Shading around the line represents the 95% confidence interval for 753 the score estimate.
- **Fig 4. Genotypic antimicrobial resistance profiles of 506** *Campylobacter* **isolates for ampicillin**
- **(AMP), ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), and tetracycline (TET)**. Isolates
- 756 were classified as susceptible if they did not possess a known resistance gene or mutation (*n* = 403).
- 757 The number of isolates possessing each resistance profile is noted above the respective bar. Error bars
- 758 are calculated from binomial confidence intervals using the Pearson-Klopper exact method.

# **Supporting Information**

- **S1 Table: Antimicrobial resistance genes and mutations used to infer phenotypic resistance in**
- **Campylobacter isolates.**
- **S2 Table. Summary of Campylobacter isolates (n = 1122) included in this study.**
- **S3 Table. Univariable results for hospitalisation, adjusted for age group, sex, and location, and**
- **final multivariable model.** OR: odds ratio, aOR: adjusted odds ratio, CI: confidence interval, ref: 765 reference category, Inf: no limit on confidence interval.
- **S4 Table. Univariable results for prescription of antibiotics following illness, adjusted for age**
- **group, sex, and location, and final multivariable model.** OR: odds ratio, aOR: adjusted odds ratio, CI: 768 confidence interval, ref: reference category, Inf: no limit on confidence interval.
- **S5 Table. Univariable results for length of diarrhoeal illness, adjusted for age group, sex, and**
- **location, and final multivariable model.** OR: odds ratio, aOR: adjusted odds ratio, CI: confidence
- 771 interval, ref: reference category, Inf: no limit on confidence interval.
- **S6 Table: Summary of multi-locus sequence type (MLST) and virulence gene prevalence in**  *Campylobacter jejuni* **and** *C. coli* **human isolates.**
- **S7 Table. Comparison of isolate virulence gene prevalence between human and retail meat**
- **isolates, Australia, 2018–2019.** N/A: no gene present, or no analysis possible due to zero levels. \* 776 indicates significant result (p < 0.05).
- **S1 Fig. Prevalence of virulence genes and gene clustering by multi-locus sequence type (MLST) for**
- *C. jejuni* **human isolates.** The colour scale represents the proportion of isolates within each MLST
- 779 expressing each virulence gene.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297105;](https://doi.org/10.1101/2023.10.16.23297105) this version posted October 17, 2023. The copyright holder for this

- It is made available under a CC-BY 4.0 International license.
- 780 **S2 Fig. Prevalence of virulence genes and gene clustering by multi-locus sequence type (MLST) for**
- 781 *C. coli* **human isolates.** The colour scale represents the proportion of isolates within each MLST 782 expressing each virulence gene.
- 783 **S3 Fig. Maximum likelihood phylogenetic tree showing the core genome relationship between** *C.*

784 *jejuni* **isolates (***n* **= 422) from humans in the Australian Capital Territory (ACT), New South Wales** 

785 **(NSW), and Queensland (Qld).** The circle lanes from inner to outer indicate jurisdiction, multilocus

- 786 sequence type (MLST), the number of class of antimicrobial genotype detected, and the number and
- 787 trait class of virulence genotype detected.
- 788 **S4 Fig. Maximum likelihood phylogenetic tree showing the core genome relationship between** *C.*
- 789 *coli* **isolates (***n* **= 84) from humans in the Australian Capital Territory (ACT), New South Wales**
- 790 **(NSW), and Queensland (QLD).** The circle lanes from inner to outer indicate jurisdiction, multilocus 791 sequence type (MLST), the number and class of antimicrobial genotype detected, and the number 792 and trait class of virulence genotype detected.
- 793 **S5 Fig. Relative importance by Gini\* coefficient of** *Campylobacter jejuni* **virulence genes for**  794 **predicting case isolates^ compared with meat isolates in Australia, 2018–2019.** \* Mean decrease in 795 Gini coefficient measures how much of each variable contributes to the homogeneity of the nodes 796 and leaves in the random forest. The higher the value of mean decrease Gini score, the higher the 797 importance of the variable. Values should be considered relative to those of other variables rather 798 than absolute values. ^Genes more common in case isolates include fliK, Cj1136, Cj1138, Cj1135, maf4, 799 neuC, rfbC, wlaN, cysC, Cj1422c, Cj1421c, gmhA2, kpsC, waaV, fcl, Cj1420c, ciaB, and Cj1419c although 800 not all differences in gene prevalence are significant (p <0.05).
- 801 **S1 File. Random Forest model outputs for** *Campylobacter jejuni* **and** *C. coli* **determining virulence**  802 **genes that predict hospitalisation or length of diarrhoeal illness in Australia, 2018–2019.**
- 803 **S2 File. Random Forest model outputs determining virulence genes that predict a human case**
- 804 **compared with retail meat and offal isolates in Australia, 2018–2019.**
- 805